)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Ikena Oncology
Ikena Oncology (IKNA) investor relations material
Ikena Oncology Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary10 Mar, 2026
Executive summary
Ongoing Phase 2b ADAPTIVE trial for IMG-007 in moderate-to-severe atopic dermatitis, with topline data expected in 2027; favorable safety profile observed to date.
Protocol amendment submitted to expand dosing regimens and optimize study design.
Key leadership additions in 2025 and early 2026, including new CEO and CMO.
Company formed via reverse merger with Ikena Oncology and $75M private placement in July 2025.
Financial highlights
Ended 2025 with $135.3M in cash, cash equivalents, and marketable securities, up from $12.1M at end of 2024, mainly due to merger and private placement.
R&D expenses for Q4 2025 were $3.3M, down from $3.8M in Q4 2024.
G&A expenses for Q4 2025 were $5.2M, up from $2.4M in Q4 2024, driven by merger-related costs and increased personnel expenses.
Net loss for Q4 2025 was $6.9M, compared to $4.8M in Q4 2024; full-year 2025 net loss was $45.3M, up from $36.6M in 2024.
Weighted average shares outstanding (common stock) increased to 4.87M in 2025 from 1.19M in 2024.
Outlook and guidance
ADAPTIVE trial enrollment on track, with topline data expected in 2027.
Continued focus on expanding safety database and differentiating IMG-007’s efficacy and safety profile.
Ongoing evaluation of Kaposi’s sarcoma risk and OX40-OX40L signaling in AD population.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Ikena Oncology
- Clinical-stage biopharma advancing IMG-007 for atopic dermatitis, post-merger with new PIPE funding.IKNA
Registration Filing29 Nov 2025 - Q3 2025 net loss was $24.8M; cash rose to $142.6M post-merger as IMG-007 advanced in trials.IKNAQ3 202512 Nov 2025
- Pending merger and cost reductions drive improved financials and strategic shift.IKNAQ2 202524 Jul 2025
- Restructuring and program focus led to lower losses and strong liquidity as strategic options are explored.IKNAQ3 202413 Jun 2025
- Q2 2024 saw narrowed losses, strong cash, and a strategic shift to IK-595 after major cuts.IKNAQ2 202413 Jun 2025
- Net loss narrowed to $49.2M in 2024 as Ikena pivots to a merger with Inmagene and restructures.IKNAQ4 20249 Jun 2025
- Q1 2025 net loss narrowed to $8.6M as Ikena awaits a pivotal merger with Inmagene.IKNAQ1 20256 Jun 2025
Next Ikena Oncology earnings date
Q1 20267 May, 2026
Ikena Oncology
Next Ikena Oncology earnings date
Q1 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage